Niagen Bioscience, Inc. (NAGE) fair value analysis

Nasdaq · Updated 2026-09-07

Niagen Bioscience, Inc. is a healthcare company that develops and commercializes nicotinamide riboside products and related nutritional supplements. The company operates in the United States and serves customers through direct-to-consumer and retail distribution channels.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, NAGE is trading at within about 10% of estimated fair value.

NAGE currently ranks #63 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $3.53
Sector: Healthcare
12-month range: $3.33–$7.89

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Low
RSI zone: Neutral
50/200-day trend: Downtrend
52-week position: The bottom quarter of its range

What our data shows for NAGE

Our model validated 7 trailing price-to-earnings windows for NAGE, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $3.33–$7.89.
The 14-day relative strength index sits at a neutral 57.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for NAGE
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

What people are saying

Follow the NAGE conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is NAGE stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), NAGE is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is NAGE's TickrTrends verdict?

NAGE's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does NAGE compare to other Healthcare stocks?

NAGE ranks #63 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is NAGE overbought or oversold?

NAGE's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

NAGE vs A · NAGE vs BAX · NAGE vs DHR · NAGE vs INVA · NAGE vs KNSA